Case Report

Disseminated *Mycobacterium peregrinum* and *Mycobacterium avium* infection in a patient with AIDS: A case report and review of literature

Chong Kei Lao a, Ting-Shu Wu a,b, Kuan-Yin Lin c, Ming-Hsun Lee a,*

a Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital Linkou Branch, Chang Gung University College of Medicine, 5 Fuzing St., Guishan Dist., Taoyuan 33305, Taiwan
b School of Medicine, Chang Gung University, 259, Wenhua 1st Rd, Guishan Dist., Taoyuan 33302, Taiwan
c Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Rd. (Zhongshan S. Rd.), Zhongsheng Dist., Taipei City 100, Taiwan

**ARTICLE INFO**

**Keywords:**

Case report
Disseminated infection
*Mycobacterium peregrinum*
Nontuberculous mycobacteria
AIDS

**ABSTRACT**

Disseminated nontuberculous mycobacterial infections are frequently recognized in patients living with human immunodeficiency virus/acquired immunodeficiency syndrome (AIDS) and *Mycobacterium avium-intracellulare* complex (MAIC) is the most common species. *Mycobacterium peregrinum* is a rapidly growing mycobacterium that accounts for 1–2% of community-acquired and healthcare-associated infections. It mainly causes skin and soft tissue infection. Disseminated infection by *M. peregrinum* has never been reported in patients with AIDS. We describe a case of disseminated co-infection of *M. peregrinum* and *M. avium* in a 33-year-old male with newly diagnosed AIDS, and review the literature regarding *M. peregrinum* infection. The patient’s bone marrow culture grew *M. peregrinum* and his blood culture grew *M. avium* The diagnosis of disseminated co-infection of *M. peregrinum* and *M. avium* was confirmed. Disseminated infection due to *M. peregrinum* is rare and diagnosis can be challenging. Due to limited case numbers, there is no treatment guideline for *M. peregrinum* nowadays. Further study is warranted for better understanding *M. peregrinum* related infections.

1. **Background**

Nontuberculous mycobacteria (NTM) are universal in the environment, including soil, animals, household water, aquatic systems, and healthcare water systems [1]. NTM comprise more than 150 species and are further divided into slowly growing mycobacteria (SGM) and rapidly growing mycobacteria (RGM) [1,2]. Around 50 species are considered human pathogens. Among people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) (PLWHA), disseminated NTM infections are more frequently recognized and *Mycobacterium avium-intracellulare* complex (MAIC) is the most common species [3]. *M. peregrinum* is a RGM and belongs to the *M. fortuitum* complex. Skin and soft tissue infection, pneumonia, bacteremia (catheter-related and primary infection), implantable cardioverter device infection, and tonsillar abscess by *M. peregrinum* have been reported, in which skin and soft tissue infection is the most common form of infection [3–11]. Disseminated infection by *M. peregrinum* is rare as *M. fortuitum* complex rarely causes disseminated infections compared to other pathogenic RGM, especially *M. chelonae* and *M. abscessus* [1]. Here we report a case of disseminated co-infection of *M. peregrinum* and *M. avium* in a patient with AIDS. To our best knowledge, this is the first HIV-infected patient reported to have disseminated *M. peregrinum* infection, provoking us to review literature of this bacterium.

2. **Case presentation**

A 33-year-old male visited our Hematology Clinic in April 2021 due to anemia for one year after receiving colon polyectomy a year ago. He also had chronic watery diarrhea after flu-like symptoms 2 months ago. Physical examinations only revealed pale conjunctivae. His hemogram showed pancytopenia with a white blood cell count of $1.7 \times 10^9/L$, a hemoglobin level of 3.9 g/dL (reticulocyte index: 0.12), and a platelet count of 134,000/μL. Folate, vitamin B12, and lactate dehydrogenase levels were within normal range. Protein electrophoresis disclosed a chronic inflammation pattern with decrease of albumin and polyclonal increase of gamma globulin (albumin 1.7 g/dL, total protein 5.7 g/dL). Ferritin level was 3,212 ng/mL. The patient was transferred to our Emergency Department on April 26, 2021. Fever with a body
temperature 39 °C was noted at triage. His C-reactive protein (CRP) level was 45.75 mg/L. Two sets of blood cultures yielded serogroup D *Salmonella enterica*. Stool analysis showed positive fecal occult blood test. Abdominal ultrasonography found hepatosplenomegaly. Bone marrow biopsy disclosed normal cellularity and iron stores, without granuloma or malignant cells. His HIV antigen/antibody combination test was positive, with an absolute CD4 T cell count of 16 cells/µL and a HIV RNA viral load of 338,610 copies/mL. Biktarvy™ (bictegravir, emtricitabine and tenofovir alafenamide) was started on April 29. Pancycopenia gradually improved after treatment. The other virology survey revealed 358 copies and 755 copies of CMV DNA/mL and EBV DNA/mL, respectively. Ganciclovir was prescribed and CMV DNA was not detectable after a 2-week course of treatment. For chronic diarrhea, colonofibroscopy showed an ulcerative mass involving ileocecal valve, cecum, and terminal ileum. Biopsy disclosed ulcer only. Repeated colonofibroscopy with biopsy found acute colitis without granuloma, malignancy, crypt abscess, viral inclusion body or parasite. For salmonellosis with elevated alkaline phosphatase (604 U/L), whole-body positron-emission tomography/computed tomography (18F-FDG PET/CT) was arranged for metastatic infection evaluation, which incidentally found prominent left mesenteric lymph nodes and lesions over left adrenal gland, stomach, and ascending colon. Esophagogastroduodenoscopy for the stomach lesion revealed superficial gastritis only. As lymphoma was highly suspected and fever persisted without definite infectious focus since May 19, bone marrow aspiration and biopsy were arranged again on June 02 and showed no evidence of malignancy or lymphoma cells. Bone marrow culture was also sent this time. Abdominal CT was arranged for lymphoma survey and showed multiple enlarged lymph nodes at mesentery, para-aortic and porta hepatis areas, an ill-defined, infiltrated and hypodense lesion (about 3 cm) at segment 5 of liver, diffuse wall thickening of jejunal and focal wall thickening of ileum. Echo-guided biopsy of liver tumor showed fatty liver with scattered tiny granulomas and many acid fast bacilli with Ziehl-Neelsen stain. One set of sputum mycobacterial culture yielded *M. avium*. Rifabutin (300 mg per day), ethambutol (1200 mg per day) and clarithromycin (500 mg twice a day) were started for suspected disseminated MAIC infection. Biktarvy™ was shifted to Triumeq™ (dolutegravir, abacavir and lamivudine) to avoid drug-drug interaction with rifabutin. Bone marrow in Myco/F Lytic culture medium disclosed growth of *M. peregrinum* by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) Biotype system (Bruker Daltonics), with scores ranging from 2.17 to 2.41. Rifabutin was discontinued and levofloxacin (750 mg administered intravenously once a day) was added. Dexamethasone was prescribed for suspected immunocompromise inflammatory syndrome (IRIS). Fever subsided and CRP level was normalized 3 weeks after addition of levofloxacin. The patient was discharged with clarithromycin, ethambutol and levofloxacin. However, after one and a half months, progressive leukopenia (white blood cell count: 3.2 × 10^9/L), anemia (hemoglobin: 6.5 g/dL) and elevated CRP level (89.9 mg/L) were noted at our outpatient clinic follow-up. Fever was noted upon admission. As treatment failure was a concern, we tried to regrow the previous *M. peregrinum* isolate from the stock culture and get the antimicrobial susceptibility profile, but the isolate failed to regrow. According to the previous antimicrobial susceptibility profiles of *M. peregrinum* in our hospital, trimethoprim-sulfamethoxazole, ciprofloxacin, moxifloxacin, amikacin, tigecycline, clarithromycin, linezolid and imipenem showed good in vitro activities against this bacterium. Thus, for a better disseminated *M. peregrinum* infection control, amikacin (500 mg twice a day), ciprofloxacin (500 mg administered orally twice a day) and clarithromycin (500 mg twice a day) were prescribed. However, his fever persisted and then dexamethasone was given for suspected IRIS. He responded well to amikacin-containing antibiotic regimen and steroid, with a normal CRP level 10 days later. He was discharged with clarithromycin, ciprofloxacin and linezolid (600 mg twice a day). Six weeks after his discharge, the hospital Central Laboratory informed about *M. avium* growth from his blood culture obtained eight weeks ago. We intended to inform the patient about his condition and suggest admission, but the patient had been hospitalized at another medical center to manage his abdominal pain. Colonofibroscopy showed an obstructive lesion at hepatic flexure. Lymphadenopathy over left neck and inguinal region was also observed. Pathology report of these lesions led to a diagnosis of Kaposi’s sarcoma with visceral involvement. His serum HHV-8 DNA level was 595,000 copies/mL. He received chemotherapy with doxorubicin hydrochloride liposome and was still hospitalized at the time of writing. The timeline of the case is presented in Fig. 1.

We tested the antimicrobial susceptibility profiles for the *M. avium* isolates. The minimum inhibitory concentration (MIC) ranges and interpretation were shown in Table 1. Both *M. avium* isolates were resistant to levofloxacin, ciprofloxacin, ethambutol and linezolid (the antimicrobial agents prescribed to treat *M. peregrinum* for this patient). Only amikacin and clarithromycin were effective against both *M. peregrinum* and *M. avium* to treat mycobacterial infection for the patient.

### 3. Discussion

Although NTM are ubiquitous in the environment, only some of them are pathogenic in humans and are mostly SGM (about 82% of cases) [2]. These NTM can cause opportunistic infections in both immunocompromised and immunocompetent patients, with various clinical manifestations. There are four main clinical syndromes: pulmonary infection, skin and soft tissue infection, lymphadenitis, and disseminated infection. Though there is no clear-cut definition for disseminated NTM infection, a consensus seems to be reached among most literatures that disseminated NTM infection is defined as isolation of NTM from blood or bone marrow [12–14]. Some literature also included isolation of NTM from liver biopsy or from ≥ 2 noncontiguous organs as disseminated infection [13–15]. Disseminated NTM infections are mainly found in patients with immunodeficiency, such as AIDS and leukemia/lymphoma, and in those with genetic defects or mutations (for examples, Mendelian susceptibility to mycobacterial disease, nuclear factor κB essential modulator mutation, signal transducer and activator of transcription 1 deficiency) or presence of anti-interferon-γ autoantibodies or anti-granulocyte–macrophage colony-stimulating factor antibodies [14,15]. In PLWHA, 70% to 94.6% of disseminated NTM infections were caused by MAIC [12,13,15].

To the best of our knowledge, this is the first description of a disseminated *M. peregrinum* infection in a patient with AIDS. *M. peregrinum*, a RGM and member of the *M. fortuitum* complex, accounts for 1 to 2% of RGM infections [1]. A total nineteen publications were reviewed on the PUBMED and MEDLINE databases and there were 21 cases (including our case) reporting *M. peregrinum* infection. The demographic characteristics, infection sites, antimicrobial susceptibilities and outcomes were summarized in Table 2. Skin and soft tissue was the most commonly infected site (n = 11, 52.4%) and 54.5% of the cases (6/11) were related to surgical site or artificial-device related infections, similar clinical behavior as other members in the *M. fortuitum* complex [1]. Catheter-related bloodstream infection, pneumonia, lymphadenitis, tonsillar abscess, and infective endocarditis by *M. peregrinum* have also been reported [2,3,5–7,10,16–18]. Nine cases (42.9%) were recorded to be immunocompromised. But *M. peregrinum* could also cause sporadic invasive infections in immunocompetent patients. Pneumonia caused by *M. peregrinum* have been reported in two patients (2/4, 50%) who were previously healthy [7,18]. With increasing numbers of NTM infections in the last few decades and improvement in methods of identifying different NTM species, a rise in *M. peregrinum* infection is anticipated and physicians should be aware of the clinical significance of *M. peregrinum*.

As previously mentioned, the majority of disseminated NTM infections in PLWHA is caused by MAIC. These patients with disseminated...
MAIC infections are usually presented as prolonged fever without obvious origin, weight loss, fatigue, abdominal pain, chronic diarrhea and hepatosplenomegaly [19]. Other opportunistic infections or common malignancies in AIDS patients share similar clinical manifestations. Our patient also presented with resembling symptoms, leading to an initial tentative diagnosis of disseminated MAIC infection. It is unlikely to differentiate between these two NTM infections by clinical symptoms. Empiric treatment will be initiated for MAIC after excluding tuberculosis if there is evidence of mycobacterial growth from specimens. Drugs effective against MAIC include macrolides, ethambutol, rifabutin, fluorquinolones and amikacin [19]. For M. peregrinum, amikacin, ciprofloxacin, clarithromycin, imipenem and linezolid showed good in vitro activities (Table 2). Although we cannot differentiate between disseminated MAIC and M. peregrinum infections before species identification, both can be inhibited by macrolides, fluorquinolones and amikacin. But accurate identification of the isolate is still crucial for definite diagnosis and appropriate treatment regimen. The treatment duration for disseminated MAIC infection is at least 12 months [19]. Due to small

### Table 1

| Antibiotics       | MIC range (µg/mL) | Interpretation |
|-------------------|-------------------|----------------|
| Clarithromycin    | 2                 | S              |
| Rifabutin         | 0.5               | S              |
| Ethambutol        | 8                 | R              |
| Isoniazid         | 4                 | –              |
| Monofloxacin      | 2                 | S              |
| Rifampin          | 16                | R              |
| Trimethoprim-sulfamethoxazole | 4/76 | R |
| Amikacin          | 16                | S              |
| Linezolid         | 32                | R              |
| Ciprofloxacin     | 16–32             | R              |
| Streptomycin      | 32                | –              |
| Doxycycline       | 32                | –              |
| Ethionamide       | 2.5               | –              |

MIC: minimum inhibitory concentration. S: susceptible. I: intermediate. R: resistant

Fig. 1. Timeline of the case.
Table 2
Previous reports of Mycobacterium peregrinum infections.

| Author               | Year | Country    | Age | Gender | Immunocompromised status | Foreign body/procedure | Type of infection (specimen) | Susceptible | Resistant | Antibiotics | Duration of treatment | Intervention                | Mortality       |
|----------------------|------|------------|-----|--------|--------------------------|------------------------|-----------------------------|-------------|-----------|-------------|------------------------|-----------------------------|----------------|
| Ishii [20]           | 1998 | Japan      | 45  | M      | –                        | –                      | Skin and soft tissue (skin tissue) | NA          | NA        | SPFX, MIN   | 7 weeks               | –                           | Survived        |
| Pagnoux [21]         | 1998 | France     | 30  | F      | DM                       | Continuous subcutaneous insulin infusion | Skin and soft tissue (abscess) | AN, CIP, IMP, CLR | NA        | CIP, IMP, AN | 3 months               | surgical drainage             | Survived        |
| Rodríguez-Gancedo [5]| 2001 | Spain      | 38  | M      | Myelomonocytic leukemia  | Hickman catheter       | Bacteremia (blood)            | AN, VA, CIP | ERM, TCN, GM, TOB, IMP, MEM, CAZ, CXM, CTX, CEF, PCN, OX, AMC, SXT, CHL, CC, RIF | VA          | NA        | catheter removal | –                      | –                           | Survived        |
| Koscielniak [10]     | 2003 | Germany    | 1.2 | M      | Interferon-gamma receptor-1 deficiency | Polyomysitis treated with infliximab | –                            | IMP, CPM     | NA        | IMP, CPM    | 1 year                 | bone marrow transplantation | Survived        |
| Marie [6]            | 2005 | France     | 68  | M      | Polymyositis treated with infliximab | –                      | Skin and soft tissue, bronchoaspiration products and BAL | NA          | AN, CIP, IMP, CLR | PCN, AM, ERM, VA, CZ, anti-tuberculous drugs | –          | –        | ICD removal               | Survived        |
| Sakai [3]            | 2005 | Japan      | 30  | F      | AIDS (CD4 count: 8 cells/µl) | –                      | Lymphadenitis (lymph node)     | NA          | NA        | IMP, CLR    | 6 weeks               | drainage                | Survived        |
| Short [22]           | 2005 | USA        | 74  | M      | –                        | Automatic implantable cardioverter defibrillator | Skin and soft tissue, bronchoaspiration products and BAL | AN, CIP, IMP, CLR | NA        | IMP, CLR    | –                      | –                           | Survived        |
| Rivera-Olivero a     | 2006 | Venezuela  | NA  | NA     | –                        | Mesotherapy             | Skin and soft tissue (biopsy/aspirates) | NA          | NA        | AN, CIP     | 4-5 months             | –                           | Survived        |
| Tsolia [16]          | 2006 | Greece     | 2   | M      | Interferon-gamma receptor-1 deficiency | Polyomysitis treated with infliximab | –                            | AN, CLR, CIP | RIF       | AN, CLR, CIP | at least 1 year         | –                           | No improvement |
| Appelgren [24]       | 2008 | Sweden     | 40  | M      | –                        | Skin and soft tissue, bronchoaspiration products and BAL | NA          | NA        | AN, CIP, IMP, CLR | 3 months               | –                           | Survived        |
| Nagao [4]            | 2009 | Japan      | 58  | F      | –                        | Artificial sheets for chest wall reconstruction | Skin and soft tissue (pus) | AN, IMP, LVX | CLR, DOX  | AN, IMP, LVX | 5 weeks               | Artificial sheet removal | Survived        |
| Swahata [7]          | 2010 | Japan      | 24  | M      | –                        | –                      | Pneumonia (sputum)             | AN, CLR, LVX, EMB | INH       | CLR, LVX, EMB | –                      | –                           | Survived        |
| Torres-Duque [17]    | 2010 | Colombia   | 17  | F      | –                        | Mechanical aortic valve | Infective endocarditis (blood, sputum) | NA          | NA        | AN, IMP, CLR, SXT, RIF, DOX, MIN | 12 months               | Biological aortic valve replacement | Survived        |
| Kamiyo [25]          | 2012 | Japan      | 83  | M      | –                        | –                      | Skin and soft tissue (skin tissue) | NA          | NA        | AN, IMP, SXT, RIF, DOX, MIN | 28 weeks               | –                           | Survived        |
| Todorova [18]        | 2015 | Bulgaria   | 72  | M      | –                        | –                      | Pneumonia (sputum)             | NA          | INH       | RIF, INH, EMB, PZA, DOX | –                      | –                           | Survived        |
| Wachholz [8]         | 2016 | Brazil     | 53  | F      | Ptotoriasis (not using immunosuppressive therapy) | –                      | Skin and soft tissue (skin tissue) | NA          | NA        | –                      | 30 days               | –                           | Survived        |
| Lazo-Vasquez [11]    | 2020 | USA        | 59  | F      | –                        | Dual-chamber permanent pacemaker | Skin and soft tissue (wound) | AN, AZL, FOX, CIP, CLR, GM, IMP, LZD, MIN, MXF, TGC, SXT | AMC, FEP, CTX, CRO, DOX, TOB | AN, IMP, LZD, MXF, SXT | 4 months               | Pacemaker removal             | Survived        |

(continued on next page)
numbers of disseminated *M. peregrinum* infection, there is no recommendation for treatment duration. In Table 2, the duration of treatment for *M. peregrinum* infection varied between different sites. For disseminated infection, it was at least 12 months. The IDSA guidelines suggest lifelong treatment for disseminated MAC infection in patients with AIDS unless they restore their immunity. The treatment duration of disseminated *M. peregrinum* infection should be individualized according to the patient’s immune status. Fortunately, the prognosis of *M. peregrinum* infection seems to be good with mortality documented in only one patient [6].

### 4. Conclusion

We presented a disseminated *M. peregrinum* infection in a patient with AIDS. Disseminated infection due to this bacterium is rare and patients affected are usually immunocompromised. Due to limited cases, there is no treatment guideline for *M. peregrinum* nowadays. Most physicians chose macrolides, fluoroquinolones, imipenem or amikacin as combination therapy for *M. peregrinum* infection. Larger numbers of isolates and cases are warranted to provide more information about the clinical features, antimicrobial susceptibility pattern and prognosis of this species.

### 5. Ethics statement

This study was approved by the Institution Review Board (IRB) of Chang Gung Medical Foundation (IRB No.: 202101410A3). Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

### Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

### Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### Acknowledgments

We thank the Bank of Bacteria, Linkou Chang Gung Memorial Hospital for providing bacterial isolates.

### References

1. Brown-Elliott BA, Wallace Jr RJ. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002;15(4):716–46.
2. Rolan N, Limongi L, Putreale AM. Mycobacterium peregrinum: an atypical and uncommon mycobacterium. A case report. Arch Bronconeumol (Engl Ed) 2020;56(1):33–5.
3. Sakai T, Kobayashi C, Shinohara M. Mycobacterium peregrinum infection in a patient with AIDS. Intern Med 2005;44(3):266–9.
4. Nagao M, Sonobe M, Bando T, Saito T, Shirano M, Matsushima A, et al. Surgical site infection due to Mycobacterium peregrinum: a case report and literature review. Int J Infect Dis 2009;13(2):209–11.
5. Rodriguez-Garcion MD, Rodriguez-Gonzalez T, Yague G, Valero-Guilin PL, Segovia-Hernandez M. Mycobacterium peregrinum bacteremia in an immunocompromised patient with a Hickman catheter. Eur J Clin Microbiol Infect Dis 2001;20(8):589–90.
6. Marie I, Heliot P, Roussel F, Hervenez PL, Feve JL, Levesque H. Fatal Mycobacterium peregrinum pneumonia in refractory polymyxinostis treated with infliximab. Rheumatology (Oxford) 2005;44(9):1201–2.
7. Sawahata M, Hagiwara E, Ogura T, Komatsu S, Sekine A, Tsuchiya N, et al. Pulmonary mycobacteriosis caused by Mycobacterium peregrinum in a young, healthy man. Nihon Koksyo Gakkai Zasshi 2010;48(11):866–70.
[8] Wachholz PA, Sette CS, Caitano do Nascimento D, Soares CT, Diório SM, Massada PF. Mycobacterium peregrinum skin infection: case report. J Cutan Med Surg 2016;20(3):249–51.

[9] Pérez-Alfonzo R, Poleo Brito LE, Vergara MS, Ruiz Dasmaco A, Meneses Rodríguez PL, Kanee Quintero CE, et al. Odontogenic cutaneous sinus tracts due to infection with nontuberculous mycobacteria: a report of three cases. BMC Infect Dis 2020;20(1).

[10] Kocnieliak E, de Boer T, Dupuis S, Naumann L, Casanova JL, Ottenhoff TH. Disseminated Mycobacterium peregrinum infection in a child with complete interferon-gamma receptor-1 deficiency. Pediatr Infect Dis J 2003;22(4):378–80.

[11] Lazo-Vasquez AF, Gonzales-Zamora JA. Mycobacterium peregrinum pacemaker pocket infection: a case report and review of the literature. Case Rep Infect Dis 2020;2020. 8831026.

[12] Varley CD, Ku JH, Henkle E, Schafer SD, Winthrop KL. Disseminated nontuberculous mycobacteria in HIV-infected patients, Oregon, USA, 2007–2012. Emerg Infect Dis 2017;23(3):533–5.

[13] Wetzstein N, Geil A, Kann G, Lahn A, Schützfort G, Kessel J, et al. Disseminated disease due to non-tuberculous mycobacteria in HIV positive patients: a retrospective case control study. PloS ONE 2021;16(7):e0254607.

[14] Lai CC, Lee LN, Ding LW, Yu CJ, Hsuheh PR, Yang PC. Emergence of disseminated infections due to nontuberculous mycobacteria in non-HIV-infected patients, including immunocompetent and immunocompromised patients in a university hospital in Taiwan. J Infect 2006;53(2):77–84.

[15] Choa CH, Chen HY, Chen CY, Huang CT, Lai CC, Hsuheh PR. Clinical features and outcomes of disseminated infections caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 2004-2008. Scand J Infect Dis 2011;43(1):9–14.

[16] Tsolia MN, Chappier A, Taprantzi P, Servitoglu M, Tassios I, Spyridis N, et al. Disseminated nontuberculous mycobacterial infection in a child with interferon-gamma receptor 1 deficiency. Eur J Pediatr 2006;165(7):458–61.